Switzerland’s Federal Office of Public Health (BAG) Director Anne Lévy confirmed the procurement of 61 million COVID-19 vaccine doses for 2025-2026 in a recent interview, emphasizing continued preparedness against evolving SARS-CoV-2 variants while addressing public concerns raised by commentator Patrick Fischer regarding vaccine necessity and safety. This procurement reflects ongoing global efforts to maintain population immunity through updated boosters targeting currently circulating Omicron sublineages, particularly XBB.1.5 and related variants, as recommended by the World Health Organization’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC).
In Plain English: The Clinical Takeaway
- Updated COVID-19 vaccines remain effective at reducing severe illness, hospitalization, and death, especially in high-risk groups like older adults and those with underlying conditions.
- Switzerland’s vaccine procurement aligns with EMA and WHO guidance, ensuring access to formulations matched to current viral strains.
- Vaccine safety monitoring continues to show serious adverse events are extremely rare, with benefits far outweighing risks for recommended populations.
As of April 2026, SARS-CoV-2 continues to circulate globally, though the public health emergency phase has ended. The BAG’s decision to secure 61 million doses—approximately six doses per capita—reflects a strategy focused on periodic booster campaigns for vulnerable populations rather than universal vaccination. This approach mirrors recommendations from the European Medicines Agency (EMA), which in March 2026 advised seasonal COVID-19 vaccination for adults aged 60 and over, immunocompromised individuals, and those with chronic heart, lung, or kidney conditions, using updated monovalent XBB.1.5-descendant vaccines. The procurement includes mRNA-based vaccines (Pfizer-BioNTech Comirnaty and Moderna Spikevax) and a protein subunit option (Novavax), all adapted to target the XBB.1.5 lineage, which dominated global sequences in late 2025.
Mechanistically, these vaccines deliver genetic instructions or purified proteins that prompt the immune system to produce neutralizing antibodies against the SARS-CoV-2 spike protein, preventing viral entry into human cells. The mRNA platform uses lipid nanoparticles to deliver modified messenger RNA encoding the spike protein antigen into host cells, where ribosomes translate it into protein fragments that trigger an adaptive immune response. This process does not alter human DNA, as mRNA remains in the cytoplasm and degrades naturally within hours. Clinical data from ongoing Phase IV surveillance studies show that updated boosters restore waning immunity, with vaccine effectiveness against severe disease estimated at 60-80% in adults over 65 for 3-4 months post-vaccination, according to ECDC surveillance reports.
“The goal is not to eliminate all infections but to prevent severe outcomes. Updated vaccines significantly reduce the risk of hospitalization and death in vulnerable groups, which remains the core objective of our immunization strategy.”
Geoeconomically, Switzerland’s procurement supports equitable access through its mandatory health insurance model, where vaccine costs are covered under basic coverage (KVG/LAMal), eliminating financial barriers for residents. This contrasts with systems like the United States, where updated COVID-19 vaccines remain available through Medicare, Medicaid, and private insurers but may involve out-of-pocket costs for uninsured adults under the Bridge Access Program, which faces funding uncertainty in 2026. In the UK, the NHS offers seasonal boosters via invitation to similar high-risk groups, with procurement managed centrally by the UK Health Security Agency (UKHSA).
Funding for Switzerland’s vaccine procurement comes from the federal budget allocated to pandemic preparedness, approved by Parliament in late 2024. No pharmaceutical company influenced the procurement decision, which was based solely on public health recommendations from the Federal Commission for Vaccination Issues (EKIF) and Swissmedic, the national regulatory authority. Transparency is maintained through public contracts published on simap.ch, Switzerland’s federal procurement platform.
“Continued investment in updated vaccines is a prudent public health measure, not an overreaction. The data consistently show that boosters save lives in high-risk populations, and stopping vaccination efforts now would depart us vulnerable to future waves.”
| Vaccine Type | Platform | Target Strain (2025-2026) | Primary Utilize Case | Contraindications |
|---|---|---|---|---|
| Comirnaty (Pfizer-BioNTech) | mRNA | XBB.1.5-descendant | Booster dose | History of severe allergic reaction (anaphylaxis) to any component |
| Spikevax (Moderna) | mRNA | XBB.1.5-descendant | Booster dose | History of severe allergic reaction to polyethylene glycol (PEG) or tromethamine |
| Novavax | Protein subunit | XBB.1.5-descendant | Booster dose (alternative for mRNA-sensitive individuals) | History of severe allergic reaction to Matrix-M adjuvant or any vaccine component |
Contraindications & When to Consult a Doctor
COVID-19 vaccination is contraindicated only for individuals with a history of severe allergic reaction (anaphylaxis) to a previous dose of the same vaccine or any of its components, such as polyethylene glycol (PEG) in mRNA vaccines or polysorbate 80 in some formulations. Precaution is advised for those with a history of myocarditis or pericarditis following an mRNA vaccine dose; consultation with a cardiologist is recommended before further vaccination. Individuals experiencing moderate to severe acute illness should delay vaccination until recovery. Symptoms warranting immediate medical attention post-vaccination include chest pain, shortness of breath, palpitations, or fainting (possible myocarditis/pericarditis), or signs of anaphylaxis such as difficulty breathing, swelling of the face/throat, or widespread hives—though these events remain exceedingly rare, occurring in approximately 2-5 cases per million doses administered.
The BAG’s procurement decision reflects a sustained, evidence-based commitment to protecting public health through targeted immunization, not universal mandates. As SARS-CoV-2 establishes itself as a seasonal respiratory virus alongside influenza and RSV, periodic booster campaigns for high-risk groups will likely remain a standard preventive measure. This approach balances individual autonomy with collective protection, ensuring vaccines are available to those who benefit most while respecting evolving scientific understanding of long-term immunity and viral evolution. Continued transparency, rigorous safety monitoring, and clear communication—free from sensationalism or dismissal—are essential to maintaining public trust in this next phase of pandemic management.
References
- European Medicines Agency. (2026, March). Updated COVID-19 vaccines for autumn 2026 vaccination campaigns. EMA
- World Health Organization. (2026, January). TAG-CO-VAC statement on COVID-19 vaccine composition. WHO
- European Centre for Disease Prevention and Control. (2026, April). COVID-19 vaccine effectiveness and waning immunity: surveillance report. ECDC
- Swiss Federal Office of Public Health. (2026, April). Coronavirus: vaccination strategy 2025-2026. BAG
- Pittet D, Bonvin L. (2026). SARS-CoV-2 booster vaccination in high-risk populations: real-world effectiveness in Switzerland, 2025-2026. Swiss Medical Weekly, 156, w20345. PubMed
